Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-01-20

Clinical Trial Update: Study Evaluating The Safety Of Xyntha In Usual Care Settings [Phase 4]

View source ↗

Summary

Pfizer's Phase 4 safety study of Xyntha in usual care settings for Hemophilia A was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xyntha (recombinant coagulation factor VIII)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 4 | Status: TERMINATED | Results posted: 2012-01-20